 | • レポートコード：MRC2303G069 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の血液培養検査市場規模が、予測期間中、CAGR 9％で増加すると推測されています。本書では、血液培養検査の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（器具、消耗品、その他）分析、種類別（手動式、自動式）分析、技術別（培養法、プロテオーム法、分子法）分析、培養種類別（バクテリア、真菌、マイクロバクテリア）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Becton, Dickinson and Company、Terumo Corporation、bioMerieux、Bruker Corporation、T2 Biosystems Inc.などが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の血液培養検査市場規模：製品別 - 血液培養検査器具の市場規模 - 血液培養検査消耗品の市場規模 - その他血液培養検査の市場規模 ・世界の血液培養検査市場規模：種類別 - 手動式血液培養検査の市場規模 - 自動式血液培養検査の市場規模 ・世界の血液培養検査市場規模：技術別 - 培養法血液培養検査の市場規模 - プロテオーム法血液培養検査の市場規模 - 分子法血液培養検査の市場規模 ・世界の血液培養検査市場規模：培養種類別 - バクテリア培養における市場規模 - 真菌培養における市場規模 - マイクロバクテリア培養における市場規模 ・世界の血液培養検査市場規模：地域別 - 北米の血液培養検査市場規模 アメリカの血液培養検査市場規模 カナダの血液培養検査市場規模 メキシコの血液培養検査市場規模 … - ヨーロッパの血液培養検査市場規模 ドイツの血液培養検査市場規模 イギリスの血液培養検査市場規模 フランスの血液培養検査市場規模 … - アジア太平洋の血液培養検査市場規模 中国の血液培養検査市場規模 日本の血液培養検査市場規模 インドの血液培養検査市場規模 … - 南米/中東の血液培養検査市場規模 ブラジルの血液培養検査市場規模 アルゼンチンの血液培養検査市場規模 サウジアラビアの血液培養検査市場規模 ・競争状況 ・市場機会・将来動向 |
The blood culture test market is poised to register a CAGR of 9% during the forecast period.
The blood testing market was significantly impacted by the number of COVID-19 cases that increased worldwide. According to the study article published in May 2022 in Scientific Reports, a machine learning model was constructed for COVID-19 diagnosis based and cross-validated on the routine blood test of 5,333 patients with various bacterial and 160 patients having COVID-19 infections. Blood cultures are used to detect the presence of bacteria or fungi in the blood, to identify the type present, and to guide treatment. Testing is used to identify a blood infection (septicemia) that can lead to sepsis, a severe and life-threatening complication. Individuals with a suspected blood infection are often treated in intensive care units, so testing is usually done in a hospital setting.
The blood is the most important factor in the body’s circulation system, along with the plasma and serum, which are widely studied for the detection of biomarkers, especially for cancer detection and early diagnosis. The growing burden of several chronic diseases has increased the demand for early and effective diagnosis, as delay in diagnosis may lead to complications and can be fatal. Therefore, these diseases are creating a burden on the healthcare system. Hence, regular monitoring and diagnosing of these diseases are recommended, which is expected to fuel the market growth during the study period. According to Globocan 2020, the new cancer cases that were diagnosed accounted for 1.92 million in 2020 globally, with 9.95 million deaths. Among all cancers, breast cancer accounted for 2.26 million new cases, followed by lung (2.20 million), prostate (1.41 million), and colon, with 1.14 million new cases in 2020.
The study article published by WHO in January 2022 stated that an estimated 100-400 million dengue infections occur each year globally. Early detection of disease progression associated with severe dengue and access to proper medical care lowers fatality rates of severe dengue to below 1%. Therefore, a decrease in mortality rate due to early diagnosis of the disease boosts the demand for timely diagnosis, thus driving the market. The increasing diversity of diseases and the growing focus on the development of better treatment options for chronic and infectious diseases drives the blood testing market globally.
Blood Culture Tests Market Trends
Automated Blood Culture Tests are Expected to Grow at a High Pace
With the need for rapid diagnosis of infections and other diseases, the automated blood culture tests segment is expected to grow at significant rates. In addition, a high adaptation of automated equipment and accuracy in the results eliminate the manual errors in the results of automated blood culture tests gaining traction in the market.
According to the World Health Organization, in 2021, an estimated 12 million people were affected by tuberculosis worldwide. Tuberculosis is one of the leading causes of death around the world. The increasing prevalence of bacterial infections, especially in underdeveloped and developing countries, is expected to boost the growth of the bacterial culture testing segment. The advent of novel diagnostic technologies in culture-based tests, reduction of diagnosis time, and early prevention of disease spreading are expected to boost the growth of the market.
The advantages associated with automated blood culture drive the growth of the market. For instance, as per the National Library article published in September 2021, automated blood culture systems are intended to make the processing of blood cultures more efficient. This is accomplished by eliminating the need for blind or terminal subcultures of bottles, reducing the number of times bottles must be handled during processing, standardizing and speeding detection of microbial growth, and maximizing blood culture sensitivity and specificity. Thus, the abovementioned factors are propelling the growth of the market.
North America is Expected to Hold Significant Share
The North American region is expected to have significant market growth over the forecast period, which is mainly attributed to well-established healthcare infrastructure and better access to diagnostics. Technological advancements, awareness regarding early diagnosis, and the treatment of infectious diseases are expected to boost market growth over the forecast period.
The rising burden of chronic diseases in the United States, such as diabetes, thyroid, and other diseases requiring blood tests, will boost the market studied. For instance, as per the National Diabetes Statistics Report, 2020, approximately 34.2 million people, or 10.5% of the US population, had diabetes. Type 1 diabetes accounted for about 5.2% of all diagnosed cases of diabetes, affecting approximately 1.6 million people in the United States.
Furthermore, the launch of technologically advanced blood tests in the country will also positively contribute to market growth. For instance, in January 2022, Eurofins subsidiary empowered launched PFAS Exposure in the United States, the direct-to-consumer at-home test to determine levels of Per- and Polyfluorinated Alkyl Substances (PFAS) in a person’s blood and measure 47 of the PFAS forever chemical compounds. Also, in August 2021, Smart Meter launched the glucose monitor for managing gestational diabetes. It provides an easy and reliable way to test, monitor, and manage blood glucose levels, ensuring that all care providers have immediate access to testing results. Thus, the abovementioned factors are propelling the growth of the market.
Blood Culture Tests Market Competitor Analysis
The blood culture test market is moderately competitive with many market players. Market players focus on new product launches, innovations, and geographic expansions. Key market players operating in the market include Becton, Dickinson and Company, Terumo Corporation, bioMerieux, Bruker Corporation, T2 Biosystems Inc., Abbott Laboratories, Luminex Corporation, Siemens Healthineers AG, F. Hoffmann-La Roche AG, and Danaher Corporation.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence of Blood Infections and Ageing Population
4.2.2 Growing Demand for Rapid Diagnostics Coupled with Product Innovations
4.3 Market Restraints
4.3.1 Lack of Appropriate Reimbursement Policies
4.3.2 High Cost of Advanced Blood Culture Techniques and Lack of Skilled Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Instruments
5.1.2 Consumables
5.1.3 Other Products
5.2 By Type
5.2.1 Manual Blood Culture Testing
5.2.2 Automated Blood Culture Testing
5.3 By Technology
5.3.1 Culture-Based
5.3.2 Proteomic Technologies
5.3.3 Molecular Technology
5.4 By Culture Type
5.4.1 Bacterial
5.4.2 Fungal
5.4.3 Micro Bacterial
5.5 By End User
5.5.1 Hospital Laboratories
5.5.2 Diagnostic Laboratories
5.5.3 Other End Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Terumo Corporation
6.1.3 bioMerieux
6.1.4 Bruker Corporation
6.1.5 T2 Biosystems Inc.
6.1.6 Abbott Laboratories
6.1.7 Luminex Corporation
6.1.8 Siemens Healthineers AG
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Danaher Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS